Skip to main content
| News

RocketVax secures partners for coronavirus vaccine in Basel

17.06.2021

RocketVax has found cooperation partners for the development of its innovative coronavirus vaccine. The University Hospital of Basel, the University of Basel and the Swiss Tropical and Public Health Institute are providing funding, research infrastructure and staff resources.

biotechnology

The University Hospital of Basel (USB), the University of Basel and the Swiss Tropical and Public Health Institute (Swiss TPH) are entering into a research cooperation with RocketVax. All four are based in Basel. Founded a year ago, the startup is developing a next-generation vaccine against COVID-19. It reportedly induces a long-lasting immune response and works more effectively against mutations. “The Basel region offers the requisite expertise and innovative ideas for further developing the vaccine,” the USB explained in a press release. “The research partners are exploiting this potential to now open a ‘window of opportunity’.”

Through seed funding of 1 million Swiss francs, the USB is enabling the preclinical research work on the vaccine that has already begun to continue. The University of Basel and the Swiss TPH are contributing their research infrastructure and staff resources to the project. The Canton of Basel-Stadt is supporting the research cooperation with a further 1 million francs. According to the USB, Switzerland and other countries stand to benefit from a vaccine made in the Basel region. The first six-month project phase was backed by Innosuisse, through funding of 1.2 million francs.

The RocketVax vaccine uses coronavirus-based vectors. Different to first-generation vaccines that only target the spike protein, it is above all characterized by the fact that it activates multiple lines of immune system defense to combat the SARS-CoV-2 virus. The aim here is to provoke a much broader antibody reaction and to reduce risks connected with viral escape mechanisms. The designed genome lacks one essential virus element needed for replication, meaning it is not infectious.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Sustainability

Evolva launches new line for manufacturers of personal care products

Evolva, a manufacturer of active ingredients based in Reinach in the canton of Basel-Landschaft, will be presenting its new product...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Record figure for startups in the Basel Area

Basel Area Business & Innovation has supported a record number of 96 company startups in 2022. The number of settlements...

Read More
Noema Pharma raises 103 million Swiss francs from investors
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Noema Pharma raises 103 million Swiss francs from investors

Noema Pharma has raised a total of 103 million Swiss francs as part of an oversubscribed Series B financing round....

Read More
Advanced Manufacturing/AI, Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Why CDMO companies choose the Basel Area as their location

Originally, this article was published by the US magazine Outsourced Pharma under the title "Why Location Matters". The article highlights...

Read More
Basel Area Business & Innovation, Innovation, Invest

Basel still the most attractive small city for business in Europe

As with last year, Basel once again features among the most attractive locations in Europe for investments. It was ranked...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Ariceum Therapeutics establishes subsidiary in Basel

The German life sciences firm Ariceum Therapeutics has established a subsidiary in Basel. This company has received support from Basel...

Read More
1 2 3 61

Do you have a question? We'd like to hear from you.